Search clinical trials for: Stem cell mobilization

Total 58844 results

Hospices Civils de Lyon

Completed

Higher Percentage of CD34+ CD38- Cells Detected by Multiparameter Flow Cytometry From Leukapheresis Products Predicts Unsustained Complete Remission in Acute Myeloid Leukemia

Acute Myeloid Leukemia

France
Azienda Ospedaliera San Giovanni Battista

Unknown

Efficacy of Biosimilar Filgrastim on the Mobilization of Hematopoietic Stem Cell CD34+ (Cluster of Differentiation 34) and on the Kinetic Engraftment

Blood Diseases

Italy
Sheba Medical Center

Completed

TevaGastrim for Stem Cell Mobilization Sibling Donors

Acute Myeloid Leukemia | Myelodysplastic Syndrome

Israel
New Mexico Cancer Care Alliance
Oxnard Foundation

Terminated

Feasibility of Thioridazine as a Mobilizing Agent for CD34+ Hematopoietic Progenitor Cells

Healthy Subjects

United States
Maria Sklodowska-Curie National Research Institute...

Unknown

Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma

Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma

Poland
Genzyme, a Sanofi Company

Completed

Plerixafor Plus Granulocyte Colony-Stimulating Factor For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Non-Hodgkin Lymphoma

Lymphoma

Japan
Sheba Medical Center

Completed

Mozobil for Autologous Stem Cell Mobilization

Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Autologous Stem Cell Transplantation | Stem Cell Mobilization

Israel
Polyphor Ltd.

Completed

Safety and Efficacy of POL6326 for Mobilization of Hematopoietic Stem Cells in Healthy Volunteers

Healthy

Germany
Genzyme, a Sanofi Company

Completed

Plerixafor Plus Granulocyte Colony-stimulating Factor (G-CSF) For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Multiple Myeloma

Multiple Myeloma

Japan
BioLineRx, Ltd.

Completed

A Phase I Study Evaluating Safety, Tolerability, PK and PD of BL-8040 for Stem Cell Mobilization in Healthy Volunteers

Mobilization of Hematopoietic Stem Cells (HSC) to Peripheral Blood (PB)

Israel
Aalborg University Hospital
Turku University Hospital; Oslo University Hospital; Helsinki University Central... and other collaborators

Terminated

Stem Cell Factor (SCF) Priming of Haematopoietic Stem Cell Grafts in Malignant Lymphoma (SCF980266)

Malignant Lymphoma

Denmark, Sweden, Finland, Norway
Genzyme, a Sanofi Company

Terminated

AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF Alone

Multiple Myeloma | Lymphoma, Non-Hodgkin's

United States
Losordo, Douglas, M.D.

Withdrawn

Stem Cell Mobilization and VEGF Gene Transfer for Heart Failure

Ischemic Congestive Heart Failure (CHF)
Washington University School of Medicine

Completed

Stem Cell Mobilization by G-CSF to Treat Severe Peripheral Artery Disease (STEMPAD)

Peripheral Vascular Diseases

United States
Genzyme, a Sanofi Company

Completed

A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM (Multiple Myeloma). (PREDICT)

Transplantation | Lymphoma (Non-Hodgkin's Lymphoma) | Hodgkin's Disease or Multiple Myeloma | Front Line Mobilization

Netherlands, France, Germany, Sweden, Spain, Italy, United Kingdom
Genzyme, a Sanofi Company

Completed

Registry of Patients Treated With Plerixafor (Mozobil®) for Haematopoietic Stem Cell Mobilization Before Autologous Transplantation

Bone Marrow / Autologous Transplants

France
University of Arkansas

Terminated

Study of Hyperbaric Oxygen Therapy in Addition to Standard Growth Factor Support for Hematopoietic Progenitor/Stem Cell Mobilization

Multiple Myeloma

United States
University of Washington
National Heart, Lung, and Blood Institute (NHLBI); Genzyme, a Sanofi Company; George Papanicolaou Hospital

Completed

Evaluating the Safety and Effectiveness of Mozobil Mobilization in Adults With Beta-Thalassemia Major

Beta-Thalassemia

Greece
WiSP Wissenschaftlicher Service Pharma GmbH

Completed

Tandem Melphalan and Autolog. SCT in MM Patients 60 to 70 Years of Age With and Without Induction Chemotherapy (DSMM-II)

Multiple Myeloma
University of Padova
Azienda Ospedaliera di Padova

Completed

Stem Cell Mobilization With Plerixafor in Diabetic vs Control Subjects

Diabetes

Italy
University Hospital, Clermont-Ferrand

Completed

Mobilization by Plerixafor of Haematopoietic Stem Cells in Children (MEP1)

Children Cancer, Solid Tumor

France
National Taiwan University Hospital

Completed

Study on the Efficacy and Mechanism of Cardiac Rehabilitation for Stem Cell Mobilization and Heart Failure Improvement

Myocardial Infarction

Taiwan
University Hospital Tuebingen

Completed

Pegfilgrastim vs. Filgrastim - Comparison of Mobilized Blood Stem Cells in Patients With Non Hodgkin-lymphoma

Non-Hodgkin Lymphoma

Germany
Polyphor Ltd.

Completed

Exploratory Study on POL6326 in Stem Cell Mobilization

Multiple Myeloma

Germany
University Hospital Inselspital, Berne

Completed

PAV-trial: Plerixafor and Chemotherapy With Vinorelbine for Stem Cell Mobilization in Patients With Myeloma (PAV)

Myeloma

Switzerland
Genzyme, a Sanofi Company

Completed

Mobilization of Stem Cells With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma Patients

Lymphoma, Non-Hodgkin

United States, Canada
Genzyme, a Sanofi Company

Completed

Mobilization of Stem Cells With Plerixafor, Chemotherapy and G-CSF in Multiple Myeloma or Non-Hodgkin's Lymphoma Patients

Lymphoma, Non-Hodgkin | Multiple Myeloma

United States
Genzyme, a Sanofi Company
AnorMED

Completed

Treatment With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients

Lymphoma, Non-Hodgkin | Multiple Myeloma

Germany
Genzyme, a Sanofi Company

Completed

AMD3100 (Plerixafor) With G-CSF in Poor Mobilizing Adult Patients Who Previously Failed Hematopoietic Stem Cell (HSC) Collection/Attempts

Autologous Stem Cell Transplantation

United States
Genzyme, a Sanofi Company

Completed

The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD)

Hodgkin Disease | Non-Hodgkin Lymphoma

United States
Genzyme, a Sanofi Company
AnorMED

Terminated

Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For Collection and for Transplantation

Multiple Myeloma

United States
Genzyme, a Sanofi Company
AnorMED

Completed

Mobilization of Stem Cells With AMD3100 (Plerixafor) and G-CSF in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients

Lymphoma, Non-Hodgkin | Multiple Myeloma

United States
Genzyme, a Sanofi Company

Completed

Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients

Multiple Myeloma

United States, Canada, Germany
Genzyme, a Sanofi Company

Completed

AMD3100 (Plerixafor) Added to a Mobilizing Regimen of Granulocyte-colony Stimulating Factor (G-CSF) to Increase the Number of Peripheral Blood Stem Cells (PBSCs) in Patients With Hodgkin's Disease

Hodgkin's Disease

United States
Genzyme, a Sanofi Company

Completed

AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSF

Lymphoma, Non-Hodgkin | Multiple Myeloma

Canada
Genzyme, a Sanofi Company

Approved for marketing

Access Program for Use of AMD3100 to Increase Peripheral Blood Stem Cells for Transplantation in Patients Who Have Failed Standard Therapy Stem Cell Mobilization (CUP)

Autologous Stem Cell Transplant
Genzyme, a Sanofi Company

Completed

Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM).

Lymphoma | Multiple Myeloma | Non Hodgkin's Lymphoma | Hodgkin's Disease

Germany
CancerCare Manitoba

Completed

Trial of an Augmented Mobilization Strategy With Plerixafor (Mozobil®) in a Population at Risk for Poor Stem Cell Mobilization

Lymphoma | Multiple Myeloma

Canada
University of Padova

Completed

Bone Marrow Progenitor Cell Mobilization in Diabetes (GCSF-DM)

Diabetes Mellitus

Italy
M.D. Anderson Cancer Center
Bayer

Completed

G-CSF Versus G-CSF Plus GM-CSF for Stem Cell Mobilization in NHL Patients

Lymphoma

United States
Terumo BCT
Yale University; Versiti; Key Biologics, LLC; LeukoLab

Completed

Evaluation of the Spectra Optia® Apheresis System Mononuclear Cell (MNC) Collection Procedure in Healthy Blood Donors

Leukapheresis

United States
City of Hope Medical Center

Completed

Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Proteonomix, Inc.
University of Medicine and Dentistry of New Jersey; Numoda

Unknown

Mobilization of Stem Cells With G-CSF and Mozobil in Patients With End Stage Liver Disease

End Stage Liver DIsease

United States
University of Washington
National Heart, Lung, and Blood Institute (NHLBI); George Papanicolaou Hospital

Completed

Evaluating the Safety of G-CSF Mobilization in Individuals With Beta Thalassemia Major

Beta-Thalassemia

Greece
Sangamo Therapeutics

Completed

Stem Cell Mobilization in Diabetic Neuropathy Subjects Receiving SB-509

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1 | Diabetic Polyneuropathy

United States
IRCCS Policlinico S. Matteo

Completed

Immunochemotherapy, in Vivo Purging, PBSC Mobilization and Autotransplant in Relapsed or Refractory Follicular Lymphoma

Follicular Lymphoma

Italy
M.D. Anderson Cancer Center
Amgen

Completed

Pegfilgrastim (Neulasta) for Stem Cell Mobilization in Patients With Multiple Myeloma

Multiple Myeloma

United States
Swiss Group for Clinical Cancer Research

Completed

Cladribine and Rituximab as Remission Induction Therapy Followed By Rituximab and Stem Cell Mobilization in Treating Patients With CLL

Leukemia

Switzerland
Korea University Anam Hospital

Completed

Effects of Atorvastatin 10 mg Versus 40 mg in Eight Months Follow-up Coronary Flow Reserve and Bone Marrow Stem Cell Mobilization in Patients With Acute Myocardial Infarction

Acute Myocardial Infarction

Korea, Republic of
Shi, Patricia, M.D.
Genzyme, a Sanofi Company

Unknown

Study of the Best Timing for Plerixafor in Autologous Hematopoietic Stem Cell Collection

Multiple Myeloma | Non-Hodgkins Lymphoma

United States

3

Subscribe